Clinical trials are built on continuity. Recruitment may fill your pipeline, but retention keeps your study viable. When participants drop out—whether due to competing responsibilities, lack of support, or unclear
Clinical trials succeed when people stay involved. Behind every protocol and data point is a person managing their health status, daily responsibilities, and uncertainty about what participation means for them
Join us at SCOPE 2026, the Summit for Clinical Operations Executives, in Orlando this February, where clinical trial leaders from around the world gather to advance innovation and collaboration in
Patient recruitment is often cited as one of the biggest bottlenecks in clinical trials. In fact, over 80% of trials globally fail to enroll on time, leading to costly timeline
Clinical trials thrive on continuity. Keeping study participants actively engaged from informed consent form to final follow-up is critical to success. Yet patient retention remains one of the biggest challenges
Clinical trials today often involve complex treatment plans, multiple visits, and detailed protocol requirements. For many participants balancing health, work, and personal responsibilities, staying consistently engaged in study activities can
Supporting patients through complex clinical trial protocols is a major challenge in research today. Study participation often requires patients to navigate complicated visit schedules, extensive travel, and unfamiliar procedures –
Modern clinical trials demand more than mass outreach and digital reach. The success of a patient recruitment strategy in biopharma now hinges on trust, clarity, and sustained engagement. Behind every
Running a successful clinical trial is never just about protocol and data, it’s about people. Behind every enrollment number is a patient making decisions, asking questions, and navigating a deeply
Clinical trials are the backbone of medical research, but their success hinges on efficient communication, participant engagement, and careful coordination among stakeholders. Unfortunately, many trials struggle with these aspects. 85%